Connect with us

Health

Experimental drug shows promise to treat Alzheimer

Published

on

New York: An experimental drug has been found to protect Alzheimer’s-inflicted mice from memory deterioration, despite a high-glycemic-index (GI) diet meant to boost blood sugar levels.

The experimental drug from the US-based Eli Lilly and Company mimics the hunger-signalling hormone ghrelin.

“The present results suggest that ghrelin might improve cognition in Alzheimer’s disease via a central nervous system mechanism involving insulin signalling,” authors of the study published in the journal Scientific Reports wrote.

“With chronic diseases like diabetes and Alzheimer’s, you need to do a long-term study,” said examiner Inga Kadish, assistant professor at University of Alabama School of Medicine at Birmingham.

“So we did an experiment with the worst-case scenario, a high-GI diet. Alzheimer’s disease has 10 or 20 risk factors and some of the strongest risk factors are diabetes or metabolic syndrome.”

In contrast to short-term administration of the “ghrelin agonista drug — which impairs insulin sensitivity and glucose tolerance, which are signs of metabolic syndrome and diabetes — the researchers found that the long-term ghrelin agonist treatment did not impair insulin signalling and glucose tolerance in Alzheimer’s disease mice fed with a high GI diet.

In the study, the Alzheimer’s disease-model mice showed a deterioration in spatial learning as they turned older — in other words, they got lost when trying to swim to a platform hidden just beneath the water surface that they previously were trained to find in a four-foot-wide pool.

The test mice fed with the ghrelin agonist and the high-GI diet showed long-term cognitive enhancement in this water maze test as compared to the mice fed with a normal diet or high-GI diet only.

The test mice also showed more activity, reduced body weight and fat mass. They also showed a beneficial impact of the long-term ghrelin agonist treatment on insulin signalling pathways in hippocampal brain tissue.

Alzheimer’s patients show significant shrinkage of the hippocampus, a part of the brain cortex that has a key role in forming new memories.

Corona

Covid toll in Karnataka is a worrying sign for state government

Published

on

 

Even though Karnataka recorded the lowest number of Covid deaths in April since the virus struck first in 2020, the state is recording a rise in the positivity rate (1.50 per cent). Five people died from the Covid infections in April as per the statistics released by the state health department. In March, the positivity rate stood around 0.53 per cent. In the first week of April it came down to 0.38 per cent, second week registered 0.56 per cent, third week it rose to 0.79 per cent and by end of April the Covid positivity rate touched 1.19 per cent.

on an average 500 persons used to succumb everyday in the peak of Covid infection, as per the data. Health experts said that the mutated Coronavirus is losing its fierce characteristics as vaccination, better treatment facilities and awareness among the people have contributed to the lesser number of Covid deaths.

During the 4th and 6th of April two deaths were reported in Bengaluru, one in Gadag district on April 8, two deaths were reported from Belagavi and Vijayapura on April 30. The first Covid case was reported in the state in March 2020 and three Covid deaths were recorded in the month. In the following month 21 people became victims to the deadly virus, and May 2020 recorded 22 deaths. The death toll recorded everyday after May crossed three digits. However, the third wave, which started in January 2

Continue Reading

Trending